TEL AVIV, Israel–(BUSINESS WIRE)–Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced that the first patient has been e…
Author: Business Wire
GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
GenSight Biologics invité à présenter aux prochaines conférences médicales et réunions scientifiques
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurod…
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees stock options to purchas…
University of Alabama at Birmingham (UAB) Health System and Humana Sign Agreement, Expanding Humana’s Medicare Advantage Provider Network in Alabama
BIRMINGHAM, Ala.–(BUSINESS WIRE)–University of Alabama at Birmingham Health System and Humana sign agreement, expanding Humana’s Medicare Advantage provider network in Alabama.
Avanzanite Bioscience annonce qu’AKANTIOR® a reçu un avis positif du CHMP et annonce l’expansion de l’entreprise dans 26 pays européens
AMSTERDAM–(BUSINESS WIRE)–Avanzanite Bioscience B.V. (« Avanzanite » ou la « société »), une société pharmaceutique spécialisée en phase de commercialisation, uniquement axée sur les médicaments pour les maladies rares, a annoncé aujourd’hui que le C…
RadiusXR Achieves ISO 13485 and MDSAP Certifications, Announces Expansion into Canadian Market
PLEASANTON, Calif.–(BUSINESS WIRE)– #Ophthalmology–RadiusXR, a leading innovator in digital health technology, is proud to announce that it has received ISO 13485 certification and the enhanced Medical Device Single Audit Program (MDSAP) certificati…
Bausch + Lomb Launches Blink™ NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink NutriTears, a clinically proven over-the-…
Samenvatting: Avanzanite Bioscience maakt bekend dat AKANTIOR® positief advies van CHMP kreeg en kondigt de uitbreiding van het bedrijf naar 26 Europese landen aan
AMSTERDAM–(BUSINESS WIRE)–Avanzanite Bioscience B.V. (“Avanzanite” of het “Bedrijf”), een gespecialiseerd farmaceutisch bedrijf in commerciële fase, uitsluitend toegespitst op geneesmiddelen voor zeldzame ziektes, maakte vandaag bekend dat de CHMP (C…
Avanzanite Bioscience berichtet, dass AKANTIOR ® ein positives CHMP-Gutachten erhalten hat und kündigt die Expansion des Unternehmens in 26 europäische Länder an
AMSTERDAM–(BUSINESS WIRE)–Avanzanite Bioscience B.V. („Avanzanite“ oder das „Unternehmen“), ein Spezialpharmaunternehmen im kommerziellen Stadium, das sich ausschließlich auf Arzneimittel für seltene Krankheiten konzentriert, gab heute bekannt, dass …
Resumen: Avanzanite Bioscience comunica que AKANTIOR® ha recibido un dictamen positivo del CHMP y anuncia su expansión a 26 países europeos
ÁMSTERDAM–(BUSINESS WIRE)–Avanzanite Bioscience B.V. (en adelante, «Avanzanite» o la «empresa»), una empresa farmacéutica especializada en fase comercial, centrada exclusivamente en medicamentos para enfermedades raras, ha anunciado hoy que el Comité…
Riassunto: Avanzanite Bioscience comunica che AKANTIOR ® ha ricevuto il parere positivo del CHMP e annuncia l'espansione aziendale in 26 paesi europei
AMSTERDAM–(BUSINESS WIRE)–Avanzanite Bioscience B.V. (“Avanzanite” o la “Società”), azienda farmaceutica specializzata nella fase di sviluppo commerciale, focalizzata esclusivamente su medicinali per malattie rare, ha annunciato oggi che il Comitato …
Avanzanite Bioscience Reports AKANTIOR® Received Positive CHMP Opinion and Announces Corporate Expansion Into 26 European Countries
AMSTERDAM–(BUSINESS WIRE)– #AK–Avanzanite Bioscience Reports AKANTIOR® Received Positive CHMP Opinion and Announces Corporate Expansion Into 26 European Countries
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will …
Warby Parker Announces Participation in the TD Cowen 8th Annual Future of the Consumer Conference
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that the Company will be presenting at the TD Cowen 8th Annual Future of the Consumer Conference …
Sightpath Medical Acquires PennVista, Strengthening Commitment to Ophthalmology Practices
BLOOMINGTON, Minn.–(BUSINESS WIRE)–Sightpath Medical, a leading provider of mobile and fixed ophthalmic surgical services, today announced that it has acquired PennVista, a premier LASIK services business providing advanced equipment and dedicated te…
NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. the “Company”) (NYSE American: NBY) announces that a quorum was reached and that all proposals in the Company’s Definitive Proxy Statement filed on April 18, 2024 with the Securities a…
Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 director…
Resumen: Nordic Group B.V., a través de su filial Nordic Pharma, Inc. (EE. UU.), anuncia el lanzamiento del gel canalicular LACRIFILL®, una nueva terapia para el síndrome del ojo seco.
BERWYN, Pensilvania–(BUSINESS WIRE)–Nordic Pharma, Inc., filial de Nordic Group B.V., ha lanzado el gel canalicular LACRIFILL, una nueva terapia para el síndrome del ojo seco en los Estados Unidos. El gel canalicular LACRIFILL es un derivado del ácid…
Nordic Group B.V. präsentiert über ihre Tochtergesellschaft Nordic Pharma, Inc. (U.S.), die Markteinführung von LACRIFILL® Canalicular Gel, einer neuartigen Therapie für trockene Augen, bekannt.
BERWYN, Pa.–(BUSINESS WIRE)–Nordic Pharma, Inc., eine Tochtergesellschaft der Nordic Group B.V., hat LACRIFILL Canalicular Gel, eine neuartige Therapie für trockene Augen, in den USA auf den Markt gebracht. LACRIFILL Canalicular Gel ist ein vernetzte…